{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:25:37Z","timestamp":1761560737387},"reference-count":36,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":1057,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1999,2]]},"abstract":"<jats:p> <jats:italic>\n            \n\t\t\t\t\t\tAim\u2007To investigate the in vivo effect of treatment with tolterodine on debrisoquine 4\u2010hydroxylation (an index of CYP2D6 activity), omeprazole 5\u2010hydroxylation (CYP2C19), omeprazole sulphoxidation (CYP3A4) and caffeine N<jats:sub>3<\/jats:sub><\/jats:italic>\u2010demethylation (CYP1A2).<\/jats:p><jats:p> <jats:italic>\n            \n\t\t\t\t\t\tMethods<\/jats:italic>\u2007Twelve healthy male volunteers (eight extensive metabolisers [EMs] and four poor metabolisers [PMs] with respect to CYP2D6) received 4\u2003mg tolterodine l\u2010tartrate orally twice daily for 6 days. All subjects were EMs with respect to CYP2C19. The subjects received single oral doses of debrisoquine (10\u2003mg), omeprazole (20\u2003mg) and caffeine (100\u2003mg) for determination of the appropriate metabolic ratios (MR). The drugs were given on separate consecutive days, before, during and after the co\u2010administration of tolterodine.<\/jats:p><jats:p> <jats:italic>\n            \n\t\t\t\t\t\tResults<\/jats:italic>\u2007Mean serum tolterodine concentrations were 5\u201310 times higher in PMs than in EMs. Serum concentrations of the active 5\u2010hydroxymethyl metabolite of tolterodine, 5\u2010HM, were not quantifiable in PMs. The mean MR of debrisoquine (95% confidence interval) during tolterodine treatment was 0.50 (0.25\u20130.99) and did not differ statistically from the values before [0.49 (0.20\u20131.2)] and after tolterodine administration [0.46 (0.14\u20131.6)] in EMs. The mean MR of omeprazole hydroxylation and sulphoxidation or caffeine metabolism were not changed in the presence of tolterodine in either EMs or PMs. Debrisoquine and caffeine had no significant effect on the AUC(1,3\u2003h) of either tolterodine or 5\u2010HM, but during omeprazole administration small decreases (13\u201319%) in these parameters were seen.<\/jats:p><jats:p> <jats:italic>\n            \n\t\t\t\t\t\tConclusions<\/jats:italic>\u2007Tolterodine, administered at twice the expected therapeutic dosage, did not change the disposition of the probe drugs debrisoquine, omeprazole and caffeine and thus had no detectable effect on the activities of CYPs 2D6, 2C19, 3A4 and 1A2. Alteration of the metabolism of substrates of these enzymes by tolterodine is unlikely to occur.<\/jats:p>","DOI":"10.1046\/j.1365-2125.1999.00865.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T04:33:20Z","timestamp":1047357200000},"page":"145-150","source":"Crossref","is-referenced-by-count":18,"title":["Tolterodine does not affect the human <i>in vivo<\/i> metabolism of the probe drugs caffeine, debrisoquine and omeprazole"],"prefix":"10.1111","volume":"47","author":[{"family":"Brynne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"B\u00f6ttiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Hall\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Bertilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1998.00501.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02201987"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6777(1998)17:5<499::AID-NAU6>3.0.CO;2-8"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)89661-6"},{"key":"e_1_2_6_6_2","first-page":"287","article-title":"Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity.","volume":"35","author":"Brynne N","year":"1997","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90104-7"},{"key":"e_1_2_6_8_2","first-page":"289","article-title":"Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes.","volume":"26","author":"Postlind H","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1997.tb02064.x"},{"key":"e_1_2_6_10_2","unstructured":"GozziP&P\u00e5hlmanISerum protein binding of tolterodine and its 5\u2010hydroxymetyl metabolite in different species.6th European Meeting of the Society for the Study of Xenobiotics: 1997 Jun 30\u2013Jul 3; Gothenberg."},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02353473"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.38"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(97)00023-X"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(00)89216-X"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(84)80042-0"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.30"},{"key":"e_1_2_6_17_2","unstructured":"GibaldiM&PerrierDPharmacokinetics Second Edition. New York: Marcel Dekker 1982."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.2307\/2683122"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)91430-1"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199512000-00004"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.00630.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199604000-00001"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00558167"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00608215"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1990.tb03827.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1985.tb02723.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199005000-00016"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1987.tb01758.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.43"},{"key":"e_1_2_6_30_2","article-title":"Inhibition of tolterodine metabolism by fluoxetine with minor change in antimuscarinic activity.","volume":"52","author":"Brynne N","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199402000-00005"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.6.2.1371482"},{"key":"e_1_2_6_33_2","article-title":"Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.","volume":"50","author":"Brynne N","year":"1998","journal-title":"Exp Toxic Pathol"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199606000-00003"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90230-9"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050163"},{"key":"e_1_2_6_37_2","first-page":"1339","article-title":"Human cytochromes P4501A1 and P4501A2: R\u2010warfarin metabolism as a probe.","volume":"23","author":"Zhang Z","year":"1995","journal-title":"Drug Metab Dispos"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.1999.00865.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1999.00865.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1365-2125.1999.00865.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1999.00865.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T07:25:33Z","timestamp":1694417133000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.1999.00865.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1999,2]]}},"alternative-id":["10.1046\/j.1365-2125.1999.00865.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.1999.00865.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,2]]}}}